-
You are viewing Orangepower as a Guest. To start new threads, reply to posts, or participate in polls or contests - you must register. Registration is free and easy. Click Here to register.
He actually has said he doesn't think the vaccines are effective and insinuated that the new strains will be invented excuses for vaccines losing their efficacy as they get distributed to the general public with other comments indicating that he thinks governments are going to impose social distancing and mask mandates on a permanent basis.
-
1
- Show all
Did this already come up....
The American Journal of Medicine now (Jan. 2021) recommends Hydroxychloroquine, Azithromycin, and Zinc for the treatment of Covid 19 outpatients.
https://principia-scientific.com/the-american-journal-of-medicine-now-recommends-hcq-for-covid19/
Seems like strange timing..
The American Journal of Medicine now (Jan. 2021) recommends Hydroxychloroquine, Azithromycin, and Zinc for the treatment of Covid 19 outpatients.
https://principia-scientific.com/the-american-journal-of-medicine-now-recommends-hcq-for-covid19/
Seems like strange timing..
-
1
- Show all
Strange indeed, given that the article they are referring to was published in AUGUST, and there has been plenty of data since.
Here is the response of the editors of the American Journal of Medicine:
The American Journal of Medicine Responds
Joseph S. Alpert, MD
Harvey B. Simon, MD
Published: February 17, 2021 DOI:https://doi.org/10.1016/j.amjmed.2021.02.001
The Editors of The American Journal of Medicine (AJM) are grateful to Dr. Heslley Machado Silva for calling our attention to the Brazilian government's misinterpretation and misuse of an article published in The American Journal of Medicine.1 As noted in Dr. Silva's commentary, the Brazilian government continues to tout hydroxychloroquine (HCQ) as a cure-all and preventive for Coronavirus disease 2019 (COVID-19) infections. The government quotes an article printed in the AJM in January 2021 but written and accepted more than 6 months earlier and posted on the PubMed website2 at that time. This article was accepted for publication at a time when scientific information concerning prevention and management of COVID-19 was rapidly evolving. The article begins by emphasizing the importance of preventive measures including facial coverings, sanitization, and quarantining. The authors then discuss 8 agents or groups of agents that have shown in vitro or possible clinical activity against various coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Subsequently, a number of these agents, including HCQ, have been shown to be ineffective or harmful in preventing or treating infection with SARS-CoV-2. The AJM is one of many publications to call attention to this evolving scientific information.3 Despite these new data, the government of Brazil continues to cite “the prestigious American Journal of Medicine” as proof that hydroxychloroquine can prevent or treat COVID-19. In other words, the Brazilian government claims that the AJM had given a seal of approval to the use of HCQ. Nothing could be further from the truth.
The AJM is neither a regulatory agency nor an arbiter of political and scientific disputes. The AJM is a vehicle of communication employed by scientists and clinicians to report information that is potentially useful to physicians throughout the world. It is completely inaccurate to claim that the AJM has endorsed a therapeutic intervention. The article that the Brazilian government quotes as “proof” of the efficacy of HCQ was posted in PubMed before studies demonstrated that HCQ does more harm than good. The results of scientific studies are always open to review and revision by later investigation. This was the case with some of the hopeful speculations in the article by McCullough et al.2 What seemed reasonable last summer based on laboratory experiments has subsequently been shown to be untrue, but the Brazilian government does not seem to have taken account of this widely available new information, as well as the crucial role of face covering, social distancing, and sanitization that are the first recommendations of McCullough et al.2 Based on the US experience in 2020, this politicization of science should not be surprising.
And from the NIH:
Monday, November 9, 2020
Hydroxychloroquine does not benefit adults hospitalized with COVID-19
A National Institutes of Health clinical trial evaluating the safety and effectiveness of hydroxychloroquine for the treatment of adults with coronavirus disease 2019 (COVID-19) has formally concluded that the drug provides no clinical benefit to hospitalized patients. Though found not to cause harm, early findings in June when the trial was stopped indicated that the drug was not improving outcomes in COVID-19 patients. Final data and analyses of the trial, which was funded by the National Heart, Lung, and Blood Institute (NHLBI), part of NIH, will appear online Nov. 9 in the Journal of the American Medical Association(link is external).
Here is the response of the editors of the American Journal of Medicine:
The American Journal of Medicine Responds
Joseph S. Alpert, MD
Harvey B. Simon, MD
Published: February 17, 2021 DOI:https://doi.org/10.1016/j.amjmed.2021.02.001
The Editors of The American Journal of Medicine (AJM) are grateful to Dr. Heslley Machado Silva for calling our attention to the Brazilian government's misinterpretation and misuse of an article published in The American Journal of Medicine.1 As noted in Dr. Silva's commentary, the Brazilian government continues to tout hydroxychloroquine (HCQ) as a cure-all and preventive for Coronavirus disease 2019 (COVID-19) infections. The government quotes an article printed in the AJM in January 2021 but written and accepted more than 6 months earlier and posted on the PubMed website2 at that time. This article was accepted for publication at a time when scientific information concerning prevention and management of COVID-19 was rapidly evolving. The article begins by emphasizing the importance of preventive measures including facial coverings, sanitization, and quarantining. The authors then discuss 8 agents or groups of agents that have shown in vitro or possible clinical activity against various coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Subsequently, a number of these agents, including HCQ, have been shown to be ineffective or harmful in preventing or treating infection with SARS-CoV-2. The AJM is one of many publications to call attention to this evolving scientific information.3 Despite these new data, the government of Brazil continues to cite “the prestigious American Journal of Medicine” as proof that hydroxychloroquine can prevent or treat COVID-19. In other words, the Brazilian government claims that the AJM had given a seal of approval to the use of HCQ. Nothing could be further from the truth.
The AJM is neither a regulatory agency nor an arbiter of political and scientific disputes. The AJM is a vehicle of communication employed by scientists and clinicians to report information that is potentially useful to physicians throughout the world. It is completely inaccurate to claim that the AJM has endorsed a therapeutic intervention. The article that the Brazilian government quotes as “proof” of the efficacy of HCQ was posted in PubMed before studies demonstrated that HCQ does more harm than good. The results of scientific studies are always open to review and revision by later investigation. This was the case with some of the hopeful speculations in the article by McCullough et al.2 What seemed reasonable last summer based on laboratory experiments has subsequently been shown to be untrue, but the Brazilian government does not seem to have taken account of this widely available new information, as well as the crucial role of face covering, social distancing, and sanitization that are the first recommendations of McCullough et al.2 Based on the US experience in 2020, this politicization of science should not be surprising.
And from the NIH:
Monday, November 9, 2020
Hydroxychloroquine does not benefit adults hospitalized with COVID-19
A National Institutes of Health clinical trial evaluating the safety and effectiveness of hydroxychloroquine for the treatment of adults with coronavirus disease 2019 (COVID-19) has formally concluded that the drug provides no clinical benefit to hospitalized patients. Though found not to cause harm, early findings in June when the trial was stopped indicated that the drug was not improving outcomes in COVID-19 patients. Final data and analyses of the trial, which was funded by the National Heart, Lung, and Blood Institute (NHLBI), part of NIH, will appear online Nov. 9 in the Journal of the American Medical Association(link is external).
Got my email Sunday about being eligible for the vaccine. And got very lucky that I found an appointment for this Saturday.
Happy that Oklahoma is moving fast with vaccines, but the signup was not easy without searching multiple locations --- hard to find open slots for vaccines. I can definitely see how some people may give up trying to find a location with open appointments. Hope they get that fixed or make it easier for people.
Happy that Oklahoma is moving fast with vaccines, but the signup was not easy without searching multiple locations --- hard to find open slots for vaccines. I can definitely see how some people may give up trying to find a location with open appointments. Hope they get that fixed or make it easier for people.
https://www.bloomberg.com/news/arti...ccine-doses-they-re-coming-say-u-s-drugmakers
U.S. Will Have Enough Vaccine for 130 Million People by End of March
On Tuesday, Johnson & Johnson said it will be ready next month to ship 20 million doses of its one-shot vaccine. That adds to a coming surge in vaccine availability, according to a Bloomberg analysis of drugmaker promises.
Along with vaccines from Pfizer Inc. and Moderna Inc., which both require two doses, the delivery targets through next month will be enough to fully vaccinate 130 million Americans.
U.S. Will Have Enough Vaccine for 130 Million People by End of March
On Tuesday, Johnson & Johnson said it will be ready next month to ship 20 million doses of its one-shot vaccine. That adds to a coming surge in vaccine availability, according to a Bloomberg analysis of drugmaker promises.
Along with vaccines from Pfizer Inc. and Moderna Inc., which both require two doses, the delivery targets through next month will be enough to fully vaccinate 130 million Americans.
-
1
- Show all
Liar. I never said they were not effective. I also never new strains will be “invented”. I said the virus will mutate like viruses do. This is comedy gold here. You people are literally insane or incapable of reading. It’s getting to the point that I’m starting to think you are all trolling me.
Sent from my iPhone using Tapatalk
Sent from my iPhone using Tapatalk
